Pharmacology

The Biopharmaceutical Development Program (BDP) provides resources for the development of investigational biological agents. The BDP supports feasibility through development and Phase I/II cGMP manufacturing plus regulatory documentation. BDP is a DCTD-dedicated facility, but projects outside of DCTD can be considered on a case-by-case basis. If you are interested in collaborating with us, please submit a consultation request at: https://next.cancer.gov/experimentalTherapeutics/form.htm or contact the BDP directly: https://frederick.cancer.gov/Science/Bdp/contacts.aspx Contacting Thi… [learn more]

The Pharmacogenetics Core is responsible for correlating outcome observations (toxicity, efficacy, survival, PK/PD) with genetic variants (germline or somatic) to identify key genetic determinants and biomarkers that predict response to specific treatments. We also evaluate the impact of genetic variants on drug metabolism, transport, and molecular targets that influence drug resistance or contribute to inter-individual variation in therapeutic outcomes. [learn more]

The PPS encompasses all scientific analyses related to pharmacology, once the specimen has been collected and stored. There is a multi-step process to evaluate how the drug is being handled by the body after administration. The first step is to measure the drug concentrations longitudinally. This step is performed by the CPP’s Bioanalytical Unit: Bioanalytical Unit The Bioanalytical Section of the CPP is responsible for the measurement of drug concentrations in samples, either clinical or nonclinical. Our facility is staffed by a PhD Staff Scientist/Deputy Head of the CPP, a … [learn more]

Thousands of molecular targets have been measured in the NCI panel of 60 human tumor cell lines. Measurements include protein levels, RNA measurements, mutation status and enzyme activity levels. You can choose to search for a target of interest, or you may browse through a list of targets. Follow the links for a target to retrieve the 60 cell line data (either text or graphical), to run COMPARE (find Targets or Compounds whose patterns correlate with a Target of interest) and to link to various databases with information (function, sequences, disease associations) about the target. To co… [learn more]

The CPP is directly responsible for the pharmacokinetic (PK) analysis of numerous Phase I and II clinical trials conducted within the NCI. In addition, the CPP provides direct PK support for many studies performed elsewhere in the extramural community. The program provides bioanalytical support (LC-MS) and pharmacokinetic-pharmacodynamic (PK/PD) modeling and simulation of investigational agents or combination therapies to predict exposure-response in future trials (Pharmacometrics Core). The CPP can also assist with determining protein binding, drug-drug interactions, concentration-effect anal… [learn more]